ImaCor Inc

ImaCor Inc develops hemodynamic ultrasound systems for critical care settings, with primary focus on transesophageal echocardiography (TEE) for ICU, cardiac surgery, surgical/trauma, and intensive care units. The company's Hemodynamic Ultrasound platform enables direct visualization of cardiac filling and function over time to assess and guide interventions for critically ill patients. Core products include the Zura Handheld device and ClariTEE Probe, deployed via the proprietary hTEE 3-Step Method. This method combines gold-standard transesophageal echo practices with critical care protocols, allowing visualization of transgastric short axis, midesophageal four chamber, and SVC views. Clinical evidence indicates hTEE made direct therapeutic impact in 66% of patients and improved hemodynamics in 80% of cases. Primary clinical applications include fluid management and preload assessment, cardiac surgery support, trauma resuscitation, LVAD (left ventricular assist device) monitoring, and differentiation of cardiac tamponade from other causes of hemodynamic compromise. The company serves surgeons, intensivists, nurse practitioners, and trauma program managers across CVICU, SICU, MICU, and ED settings. ImaCor provides comprehensive educational support including whiteboard lessons, learning modules, case studies, peer-reviewed evidence, and 24/7 technical support. The platform addresses critical gaps in bedside cardiac assessment beyond traditional indirect methods such as blood pressure, lactate, and cardiac output monitoring.